DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Amgen Announced the Result of its CodeBreak-200 Trial; FDA Clears Bristol-Myers Squibb’s Deucravacitinib; BioNTech’s Amplified CAR-T Therapy; TIL Therapy Improves on Yervoy in Melanoma; GSK’s Daprodustat will have to face FDA Advisory Committee; Breakthrough Therapy Status to Pfizer’s Group B Strep Vaccine; EU Approves Gilead’ Tecartus; Gilead’ Trodelvy Results in TROPiCs-02 Trial Visit Post
2 Alopecia Areata Treatment: Which Pipeline Therapy Will Steal the Spotlight? Visit Post
3 AstraZeneca’s Imfinzi for Biliary Tract Cancer; FDA Clears Boehringer’s Spesolimab; Novo Nordisk to Acquire Forma Therapeutics; Sanofi’s Xenpozyme Approved for ASMD; Another FDA Approval to Azurity’s Konvomep; Amgen’s Lumakras Trial Results; FDA Grants Priority Review to Sanofi & Sobi’s efanesoctocog alfa; Neurocrine Bio to Takeover UK Biotech Diurnal Visit Post
4 Which Pipeline Therapy Will Change the WHIM Syndrome Treatment Market Scenario? Visit Post
5 Aktis’s Novel Targeted Alpha Radiopharmaceuticals; Koye Partners with Sonde Health; Novartis to Spin Off Sandoz Business; Alcon to Buy Aerie Pharma; Fast Track Designation to Merck’s MK-2060; FDA Approves Ibrutinib for Chronic GvHD; French Authorities Clears BrainVectis’s Clinical Trial; Takeda’s Dengue Vaccine TAK-003 Gets Approval in Indonesia Visit Post
6 CereVasc’s eShunt System Study; FDA Approves NGS-Based CDx for Trastuzumab Deruxtecan; Nanopath Secures $10 Million Funding; BD, Accelerate Diagnostics Announce Collaboration; Avails Medical’s Clinical Trials for eQUANT; Movano Ring Exceeds Accuracy Targets for SpO2 & Heart Rate Monitoring Visit Post
7 Can FcRn Antagonists Be The Game-Changer in the Generalized Myasthenia Gravis (gMG) Treatment Market? Visit Post
8 AstraZeneca’s Imfinzi Shows Positive Results; Novartis Announces Results of Tislelizumab; FDA Grants Orphan Drug Designation to Evorpacept; EU Approves Sanofi’s Xenpozyme; Bayer’s Kerendia Approves in China; FDA Breakthrough Therapy Designation to Talquetamab; FDA Puts Clinical Hold on Sanofi’s Tolebrutinib; FDA Rejects Spero’s Tebipenem Visit Post
9 CE Mark to Ibex’s Gastric Cancer Detection System; Senseonics’s Eversense E3 Continuous Glucose Monitoring System; NEUSPERA’s NUVELLA SYSTEM; Conformal Medical Initiates CONFORM Pivotal Trial; Meridian Launches New qPCR Master Mixes for Stool Samples; Sentinel Diagnostics Launches SENTiFIT 800 Visit Post
10 GSK’s RSV Vaccine Clears Phase III Test in Adults; Roche’s Tecentriq for Adjuvant NSCLC; Owkin Bags $ 180 million from BMS; EU Approves Roche’s Mosunetuzumab; Dostarlimab Elicits Clinical Complete Response in dMMR Rectal Cancer; FDA Backs Bluebird’s CALD Gene Therapy; Takeda’s Dengue Fever Vaccine TAK-003; FDA Approves Dupilumab Visit Post
11 How At-Home Medical Equipment is Improving the Quality of Medical Care? Visit Post
12 GenScript Enters Distribution Agreement with EUROIMMUN; Biomerics’s New Facility in Galway (Ireland); MedAlliance’s SELUTION SLR DEB; OmniGuide’s RevoLix HTL Hybrid Thulium Laser; Filterlex’s CAPTIS Full-Body Embolic Protection Device; Orthofix’s M6-C Artificial Cervical Disc Visit Post
13 Bristol-Myers Squibb’s Opdivo Approval; Mirati’s KRAS-inhibitor Adagrasib; J&J and Legend Biotech’s CAR-T Carvykti Approval; Roche’s Glofitamab; Arena Pharma’s Etrasimod Phase 3 Trials; FDA Approves Dermavant’s Vtama; FDA Approves Novartis’ Cell Therapy; NICE Approves Merck’s Keytruda Visit Post
14 PTC Therapeutics’ Gene Therapy Upstaza; Sanofi and Regeneron’s Dupixent; Bayer CAR-T Collaboration with Atara; FDA Accepts Biohaven’s Zavegepant; AbbVie Files FDA Approval for ABBV-951; Innoviva to Acquire Entasis; FDA Orphan Drug Designation to XMT-2056; FDA Approves Azacitidine for Juvenile Myelomonocytic Leukemia Visit Post
15 AstraZeneca’s Farxiga; Incyte’s Jakavi; FDA Fast Track Status to HM43239 for R/R AML; Idorsia’s Insomnia Drug Quviviq; EU Approves Kymirah For Follicular Lymphoma; Perrigo Acquires HRA Pharma; Janssen Submits Marketing Authorisation Application to EMA Visit Post
16 Most Promising Therapies in the Food Allergy Treatment Market Visit Post
17 GE and Medtronic's Collaboration; Vivalink's Multi-Vital Blood Pressure Patch; Foldax's TRIA Biopolymer Surgical Aortic Heart Valve; Vektor Medical's vMap Clinical Validation Study; iSono's ATUS System; Mirvie's Test to Identify Risk of Preeclampsia Visit Post
18 VBL Therapeutics’ VB-111 (ofranergene obadenovec); BMS’s mavacamten (Camzyos); Merck’s KEYTRUDA; AstraZeneca and Daiichi’s Enhertu; Pfizer/Biohaven’s VYDURA (rimegepant); AstraZeneca’s Ultomiris; Supernus’s Viloxazine (Qlebree); AbbVie’s Rinvoq Visit Post
19 Investigating the Pipeline for Ankylosing Spondylitis Treatment Landscape Visit Post
20 Sanofi’s Rare Disease Drug Xenpozyme' Approval; FDA Approves Novartis’ Pluvicto; AstraZeneca’s Imfinzi Trial Result; FDA’s Green Signal to Argenx’ Vyvgart; ViiV Healthcare and J&J’s HIV Treatment Cabenuva; UCB's FINTEPLA Approval; Cullinan’s Update for CLN-081; MEI Pharma & Kyowa’s Zandelisib Approval Visit Post
21 Can Cannabinoids be an Effective Medicinal Substance? Visit Post
22 Noninvasix’s LIVOx™ Central Venous Oxygenation Monitor; LivaNova’s aura6000 System; Oxford BioDynamics’s EpiSwitch® CiRT; Masimo’s SedLine® Brain Function Monitoring and the SedLine Pediatric EEG Sensor; Medtronic’s NuVent™ Eustachian Tube Dilation Balloon; Conformis’s published data for Bilateral Knee Implant Study Visit Post
23 GSK’s Covifenz; Idorsia's Quviviq; GSK’s ZEJULA; EMA Expands its Nod for BMS, Eli Lilly, and Novartis Drugs; Cantex Secures Global Licence to Develop Azeliragon; Biocon Acquires Viatris’ Biosimilar Business Visit Post
24 Pfizer & Lilly's JAK Inhibitors Drug; FDA Approves Lilly's Bebtelovimab; GSK's Benlysta; Daewon’s Non-steroidal Anti-inflammatory Drug; Lilly & Innovent’s Lung Cancer Drug; Bayer’s Asundexian Visit Post
25 Mapping the Biggest Pharmaceutical Companies by Continents Visit Post
26 Immunocore’s Kimmtrak; Samsung Acquires Biogen's Biosimilar Unit; Novavax’s COVID-19 Vaccine; CHMP Approves Dupixent (dupilumab); Glenmark’s High Blood Pressure Treatment; Roche’s Faricimab; GBT’s Voxelotor Visit Post
27 Evaluating the Upcoming Drugs in Pipeline for Major Autoimmune Diseases Visit Post
28 Merck’s Gefapixant; Pfizer's Somatrogon; Gilead’s Viklury; AbbVie’s Skyrizi; Gilead's Zydelig Approvals; Lantern’s LP-184; Polpharma to Acquire Advent Visit Post
29 Siemens Healthineers’s COVID-19 Antigen Self-Test; Paragon’s R3ACT Stabilization System; Pulnovo Medical’s PADN-CFDA trial; Endotronix’s PROACTIVE-HF trial; Abbott’s Proclaim XR SCS System; RTI Surgical spins off businesses Visit Post
30 Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021 Visit Post
31 Accutar's Phase I clinical trial for AC0176; Bio-Thera's cancer drug, BAT6005; Nykode's Covid-19 vaccine trial; Heat Biologics acquires Elusys Visit Post
32 What are Monoclonal Antibodies and How Can They Treat COVID-19? Visit Post
33 Evaluation of Rapidly Evolving Parkinson’s Disease Therapeutic Market Visit Post
34 Insights into some of the Biosimilar Drugs that are approved and launched in 2021 Visit Post
35 Boston Scientific's MODULAR CRM System; Restore Medical's ContraBand clinical trial result; BD acquires Venclose; Roche differentiates mutations in Omicron; Linus's StrandDx-ASD; HelioLiver launches liquid biopsy test Visit Post
36 Analyzing the Growth of the Biosimilar Market Through Years Visit Post
37 GE Healthcare-Optellum's collaboration; Ocugen’s Covid-19 vaccine trial; Blueprint to acquire Lengo Therapeutics; Therapixel's Mammoscreen Visit Post
38 Bluebird bio may get gene therapy approved in the US; Neurocrine pens $2.6B pact with Sosei Heptares; FDA opens clearances for hepatitis C diagnostics; Twist nabs antibody discovery biotech Abveris for $190M Visit Post
39 Top Drugs To Watch in HIV (2025) Visit Post
40 Abbott's Pacemaker System; Ivantis’s Hydrus Microstent; Medtronic’s PillCam Small Bowel 3; ALung Technologies's Hemolung; AppliedVR’s EaseVRx; J&J to split into two companies; OrthAlign’s Lantern® launch; LumiThera’s Light-based Theranostic Visit Post
41 Social Determinants of Health and their Impact on COVID-19 Visit Post
42 The Evolved Gene Therapy for Hemophilia Visit Post
43 IgA Nephropathy - Navigating the Emerging Therapies and Key Companies in the Therapeutics Domain Visit Post
44 Hologic to acquire Bolder Surgical; Breakthrough Device Designation to Biological Dynamics; Luminopia declares FDA approval; HistoSonics secures Breakthrough Device Designation; Phillips-Medisize expands worldwide; PolyNovo launches NovoSorb BTM tech Visit Post
45 Brickell to Submit New Drug Application to FDA; Twin Health Raises $140M; BMS' Deucravacitinib; Lando Biopharma’s LABP-104 gets Approval; NIH Grant of $ 3 M to Amydis; FDA Grant to GenSight’ GS030 Visit Post
46 Amber Implants VCFix spinal system; iotaMotion's iotaSOFT Insertion System; Boston Scientific acquires Baylis; ReCor's Paradise Ultrasound Renal Denervation; Boston Scientific's Ranger Drug-Coated Balloon; Natera's Prospera Visit Post
47 Analyzing the Key Opportunities & Challenges in the Nutraceuticals Market Visit Post
48 Exploring the Market Potential of the Upcoming Therapies for the Myasthenia Gravis Visit Post
49 Systemic Lupus Erythematosus Treatment Market: How the Leading Companies are Countering the Rising Prevalence? Visit Post
50 AstraZeneca's Ultomiris; HebaBiz's Siroquine; Pfizer's XELJANZ; Bristol Myers Squibb's Opdivo; and Masimo's PVi Visit Post
51 LQTT secures $19M; Nanox acquires Zebra Medical Vision; Takeda leads IBD drug; Visus raises $20M Visit Post
52 Peanut Allergy Market Outlook: The Market Size Growth Sees Major Thrusts Visit Post
53 Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Major Pharma Companies Visit Post
54 Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M Visit Post
55 Essential Demands Impinge the Evolving Adult-onset Still’s Disease Treatment Market Visit Post
56 Is Antibody-mediated Rejection a Roadblock to Organ Transplantation? Visit Post
57 Lilly ink deal with MiNA; Appia Bio aims for CAR-T with $52M raise; Nuvalent raises $135M; Orchard gene therapy benefits kids Visit Post
58 Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med Visit Post
59 Kinase Inhibitors: Challenging the established Biologics as the new standard of care in autoimmune diseases? Visit Post
60 A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in Blood Cancers Visit Post
61 Hemophilia B Market: How Pipeline Therapies are Transforming the Treatment Hemisphere? Visit Post
62 A Royal Disease: Hemophilia Visit Post
63 Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer Visit Post
64 Verily - Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis Visit Post
65 Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs Visit Post
66 Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone Visit Post
67 A Bleak Pipeline and Lack of Approved Treatment Clouds the Hemophagocytic Lymphohistiocytosis Market Size Growth Visit Post
68 Thrombocytopenia Drugs Market: What Newer Agents Are Expected To Enter The Market? Visit Post
69 Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate Visit Post
70 Increasing Prevalence and Upcoming Novel Therapeutic Approaches: What is Shaping the Hepatitis D Market Outlook? Visit Post
71 Search for the Cure Continues in the Chronic Hepatitis B Treatment Market Visit Post
72 Rheumatoid Arthritis: Causes, Risk Factors, Treatment Approaches and Market Landscape Visit Post
73 Fierce Competition Lies Ahead for Pipeline Therapies in the Rheumatoid Arthritis Market Visit Post
74 The Present Rheumatoid Arthritis Treatment Market Offers a Mix-and-Match Approach Visit Post
75 Brain's immune cells research update; Moderna's COVID-19 vaccine; Pfizer funnels $200 M into CStone; Myovant's relugolix falls short in metastatic prostate cancer; Alnylam's lumasiran phase 3 result Visit Post
76 The State of Alternative Medicine In The Healthcare Visit Post
77 Healthcare Delivery System: What lies in the future? Visit Post
78 FDA rejects BioMarin's Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes Visit Post
79 Sanofi acquires Principia; FDA's Nod to Roche's Enspryng; BMS, Dragonfly's Licensing Deal Visit Post
80 Celiac Disease: The Hidden Epidemic of Gluten Sensitivity Visit Post
81 Boehringer Ingelheim; Roche demonstrated new analyses of their drugs in patients with ILDs during the American Thoracic Society (ATS) Virtual conference Visit Post
82 Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV's peanut allergy patch; Combating COVID-19 with decoy target Visit Post
83 Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks $425M deal; Tregs research updates Visit Post
84 HCQ/ CQ failure; AZ/ Catalent’s deal; Sinovac’s CoronaVac and Lilly’s Olumiant trial results Visit Post
85 R&D and Upcoming therapies Paving the Way for a Potential and Better Cure for Immune Thrombocytopenia Visit Post
86 In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit Visit Post
87 Bioelectronic Medicine: Applications and Future Prospects Visit Post
88 Moderna’s COVID-19 vaccine; AcelRx buys TetraPhase; Breakthrough designation to Baricitinib Visit Post
89 JNJ-6372 nabs FDA nods, Solid tumors treatment, Kevzara for COVID-19 Visit Post
90 First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed's shares Soares Visit Post
91 Thyroid awareness month Visit Post
92 Thyroid eye disease market: New therapies enter the TED market Visit Post
93 Tepezza receives approval; a new way to treat Alzheimer’s Visit Post
94 Imfinzi combo gets ODD; Mayzent gets EU nod; Positive results of VP-102 Visit Post
95 Thumbs down to NKTR-181, Lilly expands its insulin armamentarium Visit Post
96 Eli Lilly to acquire Dermira, Boehringer buys Enleofen’s IL-11 platform, Biogen acquires Pfizer’s Alzheimer’s drug Visit Post
97 Egg Allergy Market: Second most common food allergy but no approved therapy Visit Post
98 Allergic rhinitis market: How common is Hay fever? Visit Post
99 Global Allergic disease market Visit Post
100 Omega’s sixth funding round; Correvio’s drug failure; and BIMA acquisition Visit Post
101 Acquisition of ArQule; Synthorx; and Zentalis nabs a raise Visit Post
102 Cumberland’s methotrexate product gets approval in the US; Baker Brothers purchases stake in Kodiak’s KSI-301; Sanofi offloads Seprafilm unit to Baxter Visit Post
103 Novartis buys Medicines Co. for USD 9.7 Billion Visit Post
104 The long journey of Biosimilars: Is it an emerging opportunity? Visit Post
105 AbbVie Sells bonds to Fund Allergan takeover Visit Post
106 AZ sells EU rights for Schizophrenia to Cheplapharm; Astellas, Pandion unite to extract the potential of immunomodulation; Pear therapeutics on a journey to develop digital GI treatments with Ironwood Visit Post
107 Incyte Corporation submits positive results of trials for its drug Ruxolitinib in GvHD Visit Post
108 AngioDynamics acquires Eximo; MiroBio raises USD 33 M; Janssen submits sBLA for Stelara Visit Post
109 FDA is reviewing a dangerous way to treat Peanut Allergy Visit Post
110 Roche’s Gazyva receives FDA Breakthrough designation for Lupus nephritis Visit Post
111 Fujifilm acquires global rights to Cynata's novel therapy for GvHD; Themis raises EURO 40 million for Chikungunya vaccine; Bayer to license One Drop's digital diabetes platform Visit Post
112 Helsinn out licenses Pracinostat in South America Visit Post
113 Psoriasis Pipeline: Upcoming Psoriasis Treatments Visit Post
114 Psoriasis Therapy Market Size  Visit Post
115 Juvenile Idiopathic Arthritis Therapy Market Visit Post
116 Juvenile Idiopathic Arthritis Awareness Month Visit Post
117 PureHealth acquires LYT-100; Sosei raises USD 2.5 M Visit Post
118 Juvenile Idiopathic Arthritis Etiology and Epidemiology Visit Post
119 Osivax raises USD 9M; Smyraf launched; Revolution secures USD 100M Visit Post
120 Myasthenia gravis Market Outlook Visit Post
121 Myasthenia Gravis Awareness Month Visit Post
122 Recent Market Reports Visit Post
123 GSK to spend $100M; Lilly sell; Sherlock Bio raises $31M; Deerfield, UIC to foster research Visit Post
124 World Immunization Week Visit Post
125 Narcolepsy now a confirmed Autoimmune Disorder Visit Post
126 Notizia Visit Post
127 Notizia Visit Post
128 Notizia Visit Post
129 Notizia Visit Post
130 Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand Visit Post
131 Notizia Visit Post
132 Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M; Alexion acquired Syntimmune Visit Post
133 Outset Medical captures; Wright Medical Group to takeover Cartiva; Y-mAbs Therapeutics prepares for IPO; Biotech boom remunerates analysts Visit Post
134 AZ dragout Entasis; Sierra remunerates Gilead; Principia raises; Harbour BioMed and Kelun pen deal Visit Post
135 Fatty Acid Amide Hydrolase (FAAH) Inhibitor – an enzyme with novel therapeutic potential Visit Post
136 Celiac vaccine trial; New discovery in Nicotine; Nabriva lines up FDA filing; Rare Disease drug development accelerating Visit Post
137 Business Cocktail Visit Post
138 Business Cocktail Visit Post
139 Celiac Disease – Intestinal damage of Gluten Visit Post
140 Involvement of B cells in the pathogenesis of primary Sjögren syndrome (pSS) Visit Post
141 Notizia Visit Post
142 NOTIZIA Visit Post
143 Gaucher Disease: “Rare Disorder with High Unmet Needs” Visit Post
144 December 7 Business Cocktail Visit Post
145 Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial Visit Post
146 Celiac Disease (CD) – Upcoming therapies to break the stagnancy Visit Post
147 EMA to relocate to Amsterdam; Roche’s prospects; Amgen’s Humira Biosimilar delayed; Purdue’s opioid lawsuit Visit Post
148 Teva sells generics; Valeant trades; Roche's Genentech; J&J's next potential frontier Visit Post
149 Therapeutics and Celgene to develop therapies; Takeda’s expansion; J&J hopes to limit; Tech Prize for genome sequencing; Endocyte’s late-stage prostate cancer deal Visit Post
150 Alzeimer’s drug; Guardant Health receives approval; First Patient Dosed in Phase 1 Clinical Trial; Sunny Pharmtech and Vitruvias Therapeutics Receive FDA Approval Visit Post
151 Business Cocktail Visit Post
152 Idera’s Phase I Data; DelMar Initiates Trial; Novartis’ study; Humira gets EC approval Visit Post
153 Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post’s Cannabist; EPX-300 & JOTROL received Designation; New treatment Approved for adults Visit Post
154 Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK production issues; Shire unloads plant Visit Post
155 Allergan sell; AZ, Merck team up; Roche’s MS drug; Chinese API maker receives a warning letter Visit Post
156 Remicade’s launch; Endo cuts jobs; Analysts downgrade Pfizer; Corning $500M glass project Visit Post
157 Gilead faces lawsuit; Herceptin stalled; Lilly revs up, Abemaciclib gets nod; Key Humira patent gets struck down Visit Post
158 J&J nabs; Clovis plots Rubraca; Novartis scores EU approval; Seattle Genetics stops trials Visit Post
159 Tesaro’s Zejula; Mylan on EpiPen; Ohio sues drugmakers; ATUM, Horizon Discovery Announce deal Visit Post
160 Roche, Boehringer tout; Pfizer, Bristol-Myers got sued; FDA commissioner unveils; EpicGenetics expands Visit Post
161 Merck's Remicade; Sanofi, Regeneron set Kevzara; Novartis to sever; Teva puts women's health Visit Post
162 AZ’s benralizumab; Sanofi, Regeneron set; Nordisk preps; European countries offer Visit Post
163 Humira’s patent; Teva laying off; GSK aims; Thermo acquires Patheon; J& J's Invokana Visit Post
164 Merck sells biosimilars; AbbVie’s PARP; Pharma heads; Biogen looks to M&A Visit Post
165 Samsung biosim nod sets; Lilly's med hits; BioMarin sees pricing; Spinraza scores; Klick creates Visit Post
166 Novartis gets CAR-T drug; Shire aims to block; Xeljanz stands; Payer snubs; Lawmakers pass a bill Visit Post
167 Valeant's asset-sale; Sanofi coughs up $19.8M; Sanofi's Genzyme; India's Alkem; GSK’s inhalers Visit Post
168 Tesaro puts AstraZeneca; XELJANZ® receives; Innovus nabs; Alexion brings Visit Post
169 Letter for AstraZeneca; Patheon on API plant; Sanofi, Regeneron’s Dupixent; Cerulean Pharma and Daré Bioscience enter into deal; Lilly on price hikes Visit Post
170 Chronic Obstructive Pulmonary Disorder Visit Post
171 AstraZeneca announces; Trivitron launches; BrainStorm Cell Therapeutics validates Visit Post
172 Payers block EpiPen; Allergan charged; AbbVie's Humira; Baxter paying $18M Visit Post
173 Astellas ditches UMN Pharma; J&J, Actelion land on a price; Bayer’s pledge; Biogen to fork over $1.25B-plus Visit Post
174 Biosimilars: A benchmark in Pharmaceutical Business Visit Post
175 Systemic Lupus Erythematosus: An autoimmune disease Visit Post
176 Chronic Obstructive Pulmonary Disease (COPD): Scenario Visit Post
177 Pfizer uses; FDA approves; EMA approves; Mylan launches Visit Post
178 Sjogren's syndrome- Autoimmune Attack on Salivary and Tear Glands Visit Post
179 On World AIDS Day... Visit Post
180 Novartis Buys; FDA approves; Mayne Pharma Launches; Oxford Genetics Receives Grant Visit Post
181 Novartis eyes; Pfizer considers cashing; Mylan pushes to seal $465M; Valeant with Takeda for deal Visit Post
182 Collaborate for TYG Oncology; GE Healthcare and Valneva collaboration; UPS to Acquire Marken Visit Post
183 Biosimilar Market in India Visit Post
184 Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV Visit Post
185 Sun Pharma & ICGEB announce collaboration; Boehringer Ingelheim and Lupin Sign deal; Daiichi Sankyo Announces; Catalent Pharma Solutions partners with Samsung Bioepis; Celltrion Healthcare and Teva enters into exclusive business collaboration agreement Visit Post
186 Taltz (Ixekizumab) in Treatment of Plaque psoriasis Visit Post
187 FDA grants approval; Sanaria receives fast-track designation; Sanofi and Regeneron’s next blockbuster; Allele receives NIH grant Visit Post
188 Graft vs Host Disease (GVHD): Treatment approaches and Trends Visit Post
189 Sun Pharma forms partnership; Pfizer and DCRI collaborate; Avara Acquires AZ; ASLAN Pharmaceutical’s Collaboration; Amgen and Servier partnership Visit Post
190 BI & Duke Clinical Research Institute have expansion; BioInvent Inks Mfg. Pact; Elite Pharma, SunGen Pharma in Development & License Deal; Boehringer and Saniona Develop new Compounds; BioLineRx and I-Bridge Capital Establish; Alliance between Harvard and Tata Companies; Innovative Targeting Solutions and Johnson & Johnson Innovation collaborate Visit Post
191 The Road Less Travelled: EpiPen's Pricing Policy Visit Post
192 Rheumatoid Arthritis Market, Epidemiology and Market Forecast-2020 Visit Post
193 PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016 Visit Post
194 LAG-3 Antagonists, TIM-3 Antagonists; OX40 Agonists- Pipeline Insights, 2016 - A DelveInsight Report Visit Post
195 Systemic Juvenile Idiopathic Arthritis -Pipeline Insights, 2015 Visit Post
196 DelveInsight launches Indication Active Pharmaceutical Ingredient (API) Reports Visit Post
197 DelveInsight’s Immunology based Gene Therapy Reports Visit Post
198 Rheumatoid Arthritis Market Analysis Visit Post
199 Celecoxib first Generic Approval to Teva and Mylan from FDA Visit Post